Publication Date:
2023-11-30
Description:
Research in ophthalmic drug delivery has developed significant advances in the last few years, and efforts have been made to develop more effective topical formulations to increase drug bioavailability, efficiency, and safety. Drug delivery to the posterior segment of the eye remains a great challenge in the pharmaceutical industry due to the complexity and particularity of the eye's anatomy and physiology. Some advances have been made with the purpose of maintaining constant drug levels in the site of action. The anatomical ocular barriers have a great impact on drug pharmacokinetics and, subsequently, on the pharmacological effect.Despite the increasing interest in efficiently reaching the posterior segment of the eye with reduced adverse effects, there is still a need to expand the knowledge of ocular pharmacokinetics that allow the development of safer and more innovative drug delivery systems. These novel approaches may greatly improve the lives of patients with ocular pathologies.
Keywords:
excitotoxicity
;
neurodegeneration
;
retina
;
microparticles
;
controlled drug release
;
rebamipide
;
sustained delivery system
;
dry eye
;
eyelid
;
mucin
;
ocular pharmacokinetics
;
ocular drug delivery systems
;
ocular routes of drug administration
;
intravitreal administration
;
topical administration
;
anti-angiogenesis
;
corneal neovascularization (NV)
;
epigallocatechin gallate (EGCG)
;
gelatin
;
hyaluronic acid (HA), nanoparticles
;
RGD peptide
;
eye drops
;
retinal penetration
;
neuroprotection
;
protein aggregation
;
stability
;
intravitreal delivery
;
CNTF
;
corticosteroids
;
drug delivery systems
;
intravitreal dexamethasone implant
;
intravitreal injections
;
Ozurdex
;
drug delivery
;
glaucoma
;
ROCK inhibitor
;
fasudil
;
PLGA microspheres
;
intravitreal injection
;
trabecular meshwork
;
Schlemm’s canal
;
retinal pigment epithelium
;
Electric Cell-Substrate Impedance Sensing
;
dexamethasone acetate
;
cyclodextrins
;
hydrogels
;
rheology
;
cytotoxicity studies
;
transcorneal permeation
;
radiolabeled ocular biopermanence
;
blood-retinal barrier
;
cationic drug
;
transport
;
lysosomal trapping
;
atropine
;
ophthalmic solution
;
myopia
;
amphotericin B
;
γ-cyclodextrins
;
fungal keratitis
;
lutein
;
PLGA
;
PLGA–PEG–biotin
;
ARPE-19
;
macular edema
;
age-related macular degeneration
;
biotin-decorated nanoparticles
;
polymeric nanoparticles
;
targeted therapy
;
ocular drug delivery
;
half-life extension
;
albumin
;
therapeutic proteins
;
size exclusion chromatography
;
iron
;
retinal degeneration
;
retinitis pigmentosa
;
transferrin
;
gene therapy
;
plasmid electrotransfection
;
dexamethasone
;
poly(lactic-co-glycolic) acid
;
ophthalmology
;
microspheres
;
periocular administration
;
gamma sterilization
;
tolerance
;
in vitro model
;
in vitro drug release
;
intravitreal implants
;
SLA 3D-printing
;
triamcinolone acetonide
;
USP apparatus 4
;
USP apparatus 7
;
vitreous substitute
;
dissolution
;
bic Book Industry Communication::M Medicine
;
bic Book Industry Communication::K Economics, finance, business & management::KN Industry & industrial studies::KND Manufacturing industries::KNDP Pharmaceutical industries
Language:
English
Format:
application/octet-stream
